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Complement activation during OKT3 treatment: A possible explana-
tion for respiratory side effects. Respiratory side effects that sometimes
occur during treatment with anti-CD3 MAb OKT3 might result from
pulmonary sequestration of activated neutrophils. Therefore, we stud-
ied complement activation in relation to activation and pulmonary
sequestration of neutrophils during antirejection treatment with OKT3.
In each of nine patients studied, plasma C3a-desarg and C4b/c levels
increased compared with pretreatment values already in the first sample
taken 15 minutes alter the first dose of OKT3 (P C 0.05), with peak
values at 15 and 30 minutes, respectively. Levels of neutrophil degran-
ulation product elastase (complexed to al-antitrypsin) also increased
already at 15 minutes after the first dose of OKT3 (P C 0.05), which is
before elevated levels of the cytokines TNFa, IL-6 or IL-8 were
detectable. In contrast, upon subsequent OKT3 administrations or in
the control group treated with methylprednisolone, neither complement
activation, cytokine release nor neutrophil degranulation occurred. In
five studied patients treated with OKT3, pulmonary sequestration of
radiolabeled granulocytes was observed from 3 until 15 minutes alter
the first dose of OKT3, together with peripheral blood granulocyto-
penia, which lasted at least 30 minutes. In conclusion, we demonstrate
a simultaneous activation of complement and pulmonary sequestration
of activated granulocytes immediately following the first dose of OKT3.
These phenomena may be involved in the development of respiratory
side effects complicating this therapy.
OKT3 is an IgG2a murine monoclonal antibody (MAb) di-
rected against the CD3 molecule on T lymphocytes and is used
in the prophylaxis and treatment of acute rejection of trans-
planted organs [1, 2]. The first dose of OKT3 causes clinical
side effects including rigors, fever, headache, nausea and diar-
rhea starting usually within several hours after administration.
These side effects have been associated with systemic release of
cytokines, such as tumor necrosis factor-a (TNFa), interleu-
kin-2 (IL-2), 'y-interferon, and IL-6 [3—6], which parallel clinical
side effects. In addition, respiratory symptoms ranging from
mild dyspnea to severe respiratory distress may occur after the
first OKT3 administration [7—9]. These side effects may also
result from the release of cytokines such as TNFa [6, 10, 11].
However, respiratory symptoms generally develop within 30
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minutes following the first dose of OKT3 [8, 9] which is before
elevated levels of circulating cytokines are detected [3—6]. Since
in a previous study we demonstrated activation of coagulation
and fibrinolysis before an increase in levels of circulating
cytokines was detected [12, 13], we hypothesized that mecha-
nisms other than cytokine release may be involved in the
development of side effects upon the first administration of
OKT3. There is ample evidence that dyspnea and pulmonary
edema, in relation to conditions other than treatment with
OKT3, can be induced by complement activation products
and/or complement activated neutrophils [14—18]. Furthermore,
complement activation products themselves may induce cyto-
kine release, thus potentiating their noxious activities [10,
19—21].
Therefore, we have investigated the possible role of comple-
ment activation in the pathogenesis of side effects caused by
OKT3, by measurement of complement activation products
C3a-desarg and C4b/c in the plasma of nine renal allograft
recipients during the first three days of anti-rejection treatment
with OKT3. Furthermore, we studied neutrophil activation by
measurement of degranulation products elastase (in complex
with al-antitrypsin) and lactoferrin in relation to the aforemen-
tioned complement activation products and the cytokines
TNFa, IL-6 and IL-8. As a control group we studied eight renal
transplant recipients who were treated for acute rejection of the
allograft with methylprednisolone (MPNS) only. To study the
possible consequences of complement activation for the devel-
opment of respiratory side effects, we monitored sequestration
of 99mTc..hexamethylpropyleneamine..oxime (HMPAO) labeled
granulocytes into the pulmonary vasculature in five of the
OKT3 treated patients.
Methods
Patients
Nine renal allograft recipients (6 male, 3 female; median age
47 years, range 31 to 61 years) were studied who received
OKT3, a murine IgG2a MAb directed against the CD3 complex
(Ortho Diagnostic Systems, Raritan, New Jersey, USA) for the
treatment of acute allograft rejection. Basic immunosuppres-
sive drug therapy consisted of prednisolone (10 mg/day) and
cyclosporin A (CsA; dosage based on whole blood trough
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levels; range 150 to 200 gIliter during the first three months,
100 to 150 pg/liter thereafter). Whole blood parent compound
CsA levels were measured with a commercially available radio-
immunoassay (Cyclo-Trac; Incstar, Minnesota, USA). The
diagnosis of acute rejection was based on clinical manifesta-
tions and confirmed by histological examination of a needle
biopsy from the allograft. Overhydration, defined as an increase
in body weight of more than 3%, was evaluated by assessing
weight, fluid balance and a chest X-ray taken the day before
treatment with OKT3. Three patients underwent pretreatment
dialysis to correct fluid overload. One patient was treated with
500 mg furosemide before treatment with OKT3; there was no
suspicion of fluid overload in the other five patients. Treatment
with OKT3 consisted of a daily bolus injection of 5 mg OKT3 on
ten consecutive days. The first dose of OKT3 in each patient
was preceded by the infusion of 500 mg MPNS, over a period of
30 minutes just before OKT3 administration. In addition to
MPNS, 25 mg promethazine was administered orally. During
the first two days of treatment, blood samples were drawn just
before medication, and at 15, 30 minutes, one, two, four and six
hours after OKT3 administration. On the third day, samples
were obtained before and at one and six hours after OKT3
administration. The control group consisted of eight renal
allograft recipients (4 male, 4 female; median age 52 years,
range 36 to 60 years) who were treated for acute allograft
rejection with MPNS (500 mg/day on 6 consecutive days).
Blood samples from this control group were obtained during the
first three days of treatment, before and at one and six hours
after administration of MPNS.
Blood was collected in siliconized vacutainer tubes to which
EDTA (10 mM) and Polybrene (0.05%, wt/vol) were added to
prevent any in vitro complement activation [22]. Plasma was
collected immediately by centrifugation and was stored in
multiple aliquots at —80°C.
Total leukocyte and differential counts were determined by
flowcytometry (Technicon Hl system, Technicon Instruments,
Tarrytown, Pennsylvania, USA) in blood anticoagulated with
EDTA.
Assays for C3a-desarg and C4b/c
Plasma concentrations of C3a-desarg were measured with a
radioimmunoassay (RIA) as described before [23]. The upper
limit of values in plasma of 20 healthy controls, defined as mean
+ 2 SD, was 5 nmollliter.
Plasma levels of C4 activation products were measured with
a sandwich ELISA [24], using a murine MAb (anti-C4-1)
directed against a neo-epitope exposed on C4 activation prod-
ucts C4b, C4bi, and C4c (further designated as C4b/c) which
does not bind native C4, and a biotinylated rabbit polyclonal
antiserum against human C4 (Central Laboratory of the Neth-
erlands Red Cross Blood Transfusion Service, Amsterdam, The
Netherlands). The detection limit of the assay is 0.025 nmol/liter
and the intra- and interassay coefficients of variation are less
than 11%. The specificity of the assay has been demonstrated
by in vitro experiments in which classical or alternative com-
plement activators were added to human serum. Results from
these experiments showed that the assay only detects classical
pathway activation [24]. Samples were related to a standard
preparation that consisted of completely activated serum which
contained 2000 nmol C4b/c per liter. The upper limit of values in
plasma of 20 healthy controls, defined as mean + 2 SD, was 55
nmol/liter.
Assays for elastase-cil-antitrypsin and lactoferrin
Plasma levels of elastase-al-antitrypsin complexes and lac-
toferrin were measured with radioimmunoassays (RIA's), as
described before [25]. Samples were related to standard prep-
arations of preformed elastase-al-antitrypsin complexes or
purified lactoferrin. The upper limit of values of elastase-al-
antitrypsin and lactoferrin in plasma of 20 healthy controls,
defined as mean + 2 SD, was 3.9 n and 5.3 n, respectively.
Assays for TNF, IL-6 and IL-8
Plasma TNFa was measured with a commercially available
ELISA (Medgenix, Billerica, Massachusetts, USA). The upper
limit of values in plasma of 20 healthy controls, defined as mean
+ 2 SD, was 80 pg/ml.
Serum IL-6 was measured using the B9 bioassay [26]. Sam-
ples were related to a standard preparation of recombinant
human (rh) IL-6. In control experiments the assay was not
influenced by OKT3, CsA and MPNS concentrations occurring
in vivo (data not shown). The upper limit of values in plasma of
20 healthy controls, defined as mean + 2 SD, was 13 pg/ml.
Plasma IL-8 was measured with a sandwich ELISA, using a
coating of murine Mab (anti-IL-8 Mab 1) and a conjugate con-
sisting of a biotinylated monoclonal antibody (anti-IL-8 Mab
s-12-14) [27]. The upper limit of values in plasma of 20 healthy
controls, defined as mean + 2 SD, was 45 pg/mI.
Labeling and imaging of granulocytes
All procedures were performed with sterile, pyrogen-free
glassware and reagents. From each patient, who was to be
treated with OKT3, 46 ml fresh venous blood was collected and
suspended into 10 ml acid citrate dextrose and 4 ml plasma.
After sedimentation of erythrocytes for 45 minutes, supernatant
was collected and centrifuged at 200 g for 10 minutes. The pellet
of leukocytes was resuspended in 3 ml plasma and centrifugated
over a two-step Percoll gradient. Granulocytes were collected,
resuspended in NaCI 0.9% and incubated for 20 minutes at 20°C
with 925 MBq ofmTc HMPAO (Amersham, Amersham, UK),
which was prepared as described [28]. After centrifugation the
cell pellet was resuspended in 2 ml NaC1 0.9% and reinjected
into the patient. The administered dose varied between 300 and
500 MBq, depending on the number of collected granulocytes.
After two hours, when nonspecific pulmonary sequestration of
labeled granulocytes had vanished, infusion of MPNS was
started. During MPNS infusion mTc HMPAO granulocyte
counts over the lungs were monitored. Then, the first intrave-
nous bolus injection of 5 mg OKT3 was administered.
We monitored the sequestration of 99mTc HMPAO labeled
granulocytes into the pulmonary vasculature during the first 30
minutes after the first OKT3 administration in five of eight
patients treated with OKT3. Since pulmonary sequestration of
99mTc HMPAO labeled granulocytes was monitored during the
period of MPNS administration, these patients served as their
own controls for the effects of MPNS administration on pulmo-
nary accumulation of granulocytes. Since most patients expe-
rienced rigors and fever, usually starting from 45 to 60 minutes
after the first OKT3 administration, we did not extend the
monitoring period beyond 30 minutes. Sequestration of labeled
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granulocytes, and cell numbers in the peripheral blood were
calculated as the percentage relative to pretreatment counts.
Each patient sat in a semi-upright position in front of a large
field of view gamma camera (Siemens, Germany) mounted with
a low energy collimator. Counts per pixel were plotted against
time. Images were acquired in 60 seconds time frames on a
DEC/PDP1 1/23 computer system.
In vitro complement activation by OKT3
The ability of OKT3 to bind C3b on T cells was determined
by FACS® analysis (Becton and Dickinson, Mountain View,
California, USA). Heparinized blood was collected from three
healthy subjects. Mononuclear cells (PBMC) were separated by
centrifugation on Ficoll-Paque (density 1.076; Pharmacia, Upp-
sala, Sweden). PBMC were incubated for 30 minutes at 37°C
with 1 g/ml FITC-labeled OKT3 (Ortho Diagnostic Systems),
that is, at a similar concentration as the plasma peak level
occurring shortly after the first dose of OKT3 [291, in the
presence of fresh autologous serum. Control experiments in-
cluded incubation with heat inactivated serum (45 minutes at
56°C) or fresh serum containing EDTA (10 m final concentra-
tion). After incubation with FITC-labeled OKT3 and serum,
cells were incubated with a biotinylated MAb directed against a
neo-epitope on C3b, C3bi and C3c (anti-C3-28) [30], followed by
incubation with streptavidin-PE (Beckton Dickinson).
In vitro studies on OKT3-mediated aggregation of
granulocytes and lymphocytes
Heparinized blood and serum were obtained from three
healthy volunteers. Granulocytes were purified from the hepa-
rinized blood as described [31], resuspended in incubation
medium [321 and kept at room temperature. Plastic culture
bottle nonadherent PBMC, further referred to as lymphocytes,
were collected, resuspended in incubation medium and kept at
room temperature. These cell suspensions always contained
less than 1% monocytes (defined as CD14 positive cells).
Aggregation studies of granulocytes and lymphocytes were
performed under continuous stirring in siliconized special glass
cuvettes (Helima GmbH & Co., MUllheim, Germany) at 37°C
[32]. After mixing of equal volumes of the granulocyte and
lymphocyte suspensions, each containing 5 x cells/ml, the
aggregation stimulus was added, consisting of either: (1) fresh
autologous serum containing a concentration of OKT3 that
resulted in a final concentration of I pg/ml of OKT3 in the
cell-suspension; (2) heat-inactivated autologous serum with the
same concentration of OKT3 as in 1; or (3) fresh autologous
serum containing a concentration of an IgG2a control MAb
directed against TNP antigens without reactivity with human
blood cells or immunoglobulins (Central Laboratory of the
Blood Transfusion Service) resulting in a final concentration of
1 g/ml MAb in the cell-suspensions. From the cell-suspensions
cytospin slides were made, fixed and stained with MayGrun-
wald/Giemsa. Slides were examined by light microscopy.
Statistical analysis
Values are presented as mean SEM. Statistical analysis was
performed with the Wilcoxon signed ranks test. A P value less
than 0.05 was considered to be significant.
Results
Among the nine patients treated with OKT3, three experi-
enced dyspnea, starting in two of these patients within ten
minutes after the first dose of OKT3, in the third patient at one
hour. In contrast, none of the eight patients treated with MPNS
suffered from dyspnea. There were no significant differences in
pre-treatment clinical and laboratory parameters (sex, age,
pretreatment weight vs. dry weight, granulocyte and lympho-
cyte counts, previous hemodialysis and treatment with fu-
rosemide) of those OKT3 treated patients who did and those
who did not develop respiratory side effects. Overhydration
was always corrected before the first administration of OKT3.
Complement activation in vivo
In all OKT3-treated patients, plasma C3a-desarg levels in-
creased, from 6.1 1.0 nmol/liter (mean SEM) before the first
dose of OKT3 to a peak level of 22.9 2.8 nmol/liter in the first
sample taken at 15 minutes (P < 0.05; Fig. 1). C3a-desarg levels
declined rapidly but remained significantly elevated as com-
pared to pre-treatment values until one hour after the first dose
of OKT3. C4b/c levels in plasma increased from 57 6
nmol/liter before the first OKT3 dose to a peak level of 119 12
nmol/liter at 30 minutes (P < 0.05). These levels remained
significantly increased until two hours after the first dose of
OKT3.
Elevated plasma levels of C3a-desarg or C4b/c were detected
neither after OKT3 administration on the second and third day
of treatment (Fig. 1) nor in the control group of patients treated
with MPNS only (data not shown). Although the sampling
frequency in the latter group of patients included less time
points than in the OKT3 treated group (as described in Meth-
ods), plasma samples taken at 60 minutes after the first OKT3
administration still contained significantly elevated levels of
C3a-desarg and C4b/c (Fig. 1), whereas the control group of
MPNS treated patients had normal levels. Therefore, we con-
sider it unlikely to have missed early activation of complement
in the MPNS-treated patient group. In the OKT3 treated
patients there was no significant correlation between the extent
of complement activation and the development of respiratory
side effects.
The results indicate activation of the classical complement
pathway in the patients receiving OKT3. To exclude comple-
ment activation by aggregates in the OKT3 preparations, we
incubated various concentrations of OKT3 (in a concentration
range from 0 up to 100 g/ml) with fresh serum, and determined
C3a-desarg concentrations in the mixtures. The spontaneous
complement activation measured in the presence of OKT3 was
not different from that when PBS was added instead of OKT3,
and was less than 5% of C3a-desarg levels that were measured
when aggregated IgG was added (data not shown), excluding
complement activation by OKT3-aggregates.
Neutrophil degranulation and cytokine release in vivo
From the group of nine patients that were treated with OKT3,
eight showed a similar response to the first dose of OKT3. One
patient (male, age 38 years) who was treated with OKT3
showed a distinct response to the first OKT3 administration and
will, therefore, be discussed separately. In the group of eight
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patients, plasma levels of elastase-al-antitrypsin significantly
increased from 4.6 0.7 n before OKT3 administration to 8.7
1.6 flM, already in the first sample taken 15 minutes after the
first dose of OKT3 (P <0.05; Fig. 2). Levels increased more
gradually after one hour and reached their maximum of 11.8
1.8 n at six hours. Plasma lactoferrin levels, which amounted
3.5 0.7 n before the first dose of OKT3, were not elevated
until one hour and were first significantly increased (10.1 2.2
nM) at two hours (P < 0.05), reaching their peak of 11.4 2.2
flM at four hours. For both elastase-al-antitrypsin and lacto-
ferrin no significant changes were found after the second and
third dose of OKT3.
Fig. 1. Plasma C3a-desarg (U) and C4b/c (A)
levels in nine patients during treatment with
OKT3. Results are shown as mean (± 5EM)
for 9 patients during the first 3 days of
treatment with OKT3. Arrows indicate the
daily administration of OKT3. Time points
shown are: before, and at 15, 30, 60, 120, 240,
360 minutes after OKT3 administration on the
first 2 days; before, and at 60 and 360 minutes
after OKT3 administration on the third day.
Significant increases (P < 0.05) compared to
pre-treatment levels are indicated by an
asterisk (Wilcoxon Signed Ranks Test).
Fig. 2. Plasma elastase-al-antitrypsin (A)
and lactoferrin (•) levels in eight patients
during treatment with OKT3. Arrows indicate
the daily administration of OKT3. Results are
shown as mean values (± 5EM) for eight
patients during the first 3 days of treatment
with OKT3. For further explanation of this
figure see legend to Figure 1.
Before the first administration of OKT3, plasma levels of
TNF were 75 13 pg/mi. Compared with pretreatment values,
plasma TNF levels were first significantly elevated at half an
hour after the first dose of OKT3 (325 64 pg/ml), and reached
peak levels at one hour (516 76 pg/mi). They remained
significantly increased until six hours. Upon subsequent admin-
istrations of OKT3, plasma TNF levels did not increase. Figure
3 shows that serum IL-6 levels significantly increased from 26
7.6 pg/mi before OKT3 administration to a peak of 130 34.7
pg/mi at two hours after the first administration of OKT3 (P <
0.05). The plasma level of IL-8 increased from 25.9 4.9 pg/ml
before treatment to 1111 210 pg/mi at two hours after the first
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Fig. 3. Plasma IL-6 (•) and IL-S (A) levels in
eight patients during treatment with OKT3.
Results are shown as mean values (± sEM) for
eight patients during the first 3 days of
treatment with OKT3. For further explanation
of this figure see legend to Figure 1.
--
Fig. 5. Sequestration of 99mTc HMPAO labeled granulocytes in the
pulmonary vasculature. Results are shown as mean (± SEM) for 5 OKT3
treated patients. Pulmonary sequestration of ssmTc HMPAO labeled
granulocytes (•) and the number of granulocytes in the peripheral
4 6 blood (•) were calculated as the percentage relative to pretreatment
values. Before administration of OKT3, mean pulmonary counts of
labeled granulocytes (± 5EM) mounted 199.4 54.3 counts per pixel;
the number of granulocytes in the peripheral blood mounted 6.6 1.0
x 109/liter. Significant changes (P < 0.05) compared to pretreatment
levels are indicated by an asterisk (Wilcoxon Signed Ranks Test).
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Fig. 4. Plasma C3a-desarg (s), elastase-al-antitrypsin (A) and lacto-
ferrin (•) in one patient without elevation of circulating cytokine levels
after the first dose of OKT3. The arrow indicates administration of
OKT3. Timepoints shown are: before and at 15, 30, 60, 120, 240, 360
minutes after the first OKT3 administration.
OKT3 administration (P < 0.05). For IL-6 and IL-8, no signif-
icant increases were observed upon subsequent OKT3 admin-
istrations. Although the actual values of circulating cytokines
varied considerably, as is reflected by the SEM, the kinetics of
these parameters within each of these eight OKT3 treated
patients were comparable.
In the control group of eight patients treated for acute
0 5 10 15 20 25 30
Time, minutes after OKT3
rejection of the renal allograft with MPNS only, no increases
were found in circulating elastase-al-antitrypsin, lactoferrin,
TNF, IL-6 or IL-8 (data not shown).
The one patient that showed a distinct response to the first
dose of OKT3 did not show any increase in plasma levels of
TNF, IL-6 or IL-8 during the first day of treatment with OKT3.
Administration of OKT3 was proven by detection of therapeu-
tic levels of OKT3 in the plasma samples. In this patient, the
first dose of OKT3 did induce complement activation, since
plasma content of complement activation product C3a-desarg
Raasveld et a!: Complement activation during OKT3 treatment 1145
0 200 400 60010
C., I
S2 10 I
01
a)102 I
l20 101 314
io° ,•
100 101 102 10 10
Fluorescence 1 (0KT3)
increased similarly to that in the other eight patients (Fig. 4).
Remarkably, plasma elastase-s1-antitrypsin content showed an
increase at 15 and 30 minutes after the first dose of OKT3,
comparable to that observed in the other eight OKT3 treated
patients. In contrast, this increase in plasma elastase-crl-anti-
trypsin level was immediately followed by a continuous and
steady decline. In sharp contrast to the findings in the other
eight OKT3 treated patients, plasma levels of lactoferrin did not
increase at all in this patient.
Sequestration of granulocytes in the lung
No pulmonary sequestration of mTc HMPAO granulocytes
occurred in any patient during infusion of MPNS before the first
dose of OKT3. However, sequestration of 99mTc HMPAO
labeled granulocytes in the pulmonary circulation occurred in
each of five patients and, as compared to pre-treatment values,
was significant at three minutes after the first dose of OKT3
(P < 0.05), reaching its maximum of 126 4.2%at five minutes.
Sequestration of mTc HMPAO granulocytes in the lungs
remained significantly elevated until 15 minutes and returned to
pretreatment values at 30 minutes (Fig. 5). Pulmonary accumu-
lation of granulocytes coincided with a fall in circulating gran-
ulocytes reaching a nadir of 57% 6.1 at five minutes. The
percentage of circulating granulocytes remained decreased until
30 minutes after the first dose of OKT3 (P < 0.05).
To study possible mechanisms of granulocyte retention in the
pulmonary vasculature, we performed several in vitro experi-
ments on complement mediated interactions between lympho-
cytes and granulocytes.
Complement mediated aggregation of lymphocytes and
granulocytes in vitro
Figure 6 shows the results of a representative FACS experi-
ment on in vitro C3b fixation by OKT3 coated T cells. Upon
incubation with 10% (vol/vol) fresh autologous serum, C3b was
fixed on virtually all T cells (Fig. 6a). This was neither observed
with 10% (vol/vol) heat-inactivated serum (Fig. 6b), nor in the
presence of EDTA (data not shown). The biological significance
of this complement fixation on T cells is shown in Figure 7a.
When fresh autologous serum and OKT3 were added to a
mixture of granulocytes and lymphocytes, aggregation between
granulocytes and lymphocytes occurred. This aggregation did
not occur when heat-inactivated serum was added instead of
Fig. 6. C3b deposition on OKT3 positive
lymphocytes. FITC-labeled OKT3 (I sg/ml)
400 and a biotinylated monoclonal antibody
(second step: streptavidin-PE) against C3b
200 (anu-C3-28) were used to detect C3b fixation
on T cells. A. Virtually all OKT3 positive
cells incubated with 10% fresh autologous0 serum fixed C3b. B. Absence of C3 fixation
when heat-inactivated serum was used.
Lymphocytes were gated on forward and
sideward scatter.
fresh serum (Fig. 7b), or with the control IgG2a MAb (data not
shown).
Discussion
Murine MAbs of the IgG2a subclass are able to activate
human complement in vitro [33]. Therefore, complications
occurring upon administration of murine MAbs to humans may
be caused by complement activation products. Surprisingly, in
the context of OKT3 administration to humans, only two
studies have been reported on complement activating proper-
ties of OKT3 in vitro [34, 35] and—to the best of our knowl-
edge—no prior studies have been published on in vivo comple-
ment activation by OKT3 in humans. Presumably, this is due to
the general belief that murine MAbs only weakly activate
human complement [36].
Current research on side effects caused by treatment with
OKT3 focuses on cytokines as possible causative agents [3—6].
In mice and in humans, pre-administration of high dose meth-
ylprednisolone reduced both anti-CD3-induced cytokine release
and toxic side effects [37, 38]. However, a recent study by
Zlabinger et al in renal transplant recipients on side effects of
OKT3 and the IgG2b murine monoclonal antibody BMAO3 1,
which is directed against the a//3 T cell receptor, indicated that
elevated circulating levels of cytokines cannot produce morbid-
ity by itself [39]. In addition, respiratory side effects and
hypotension that occur early after the start of treatment with
OKT3 [8, 9] remain largely unexplained [401, although cyto-
kines such as TNFa may be involved [6, 10, 11]. Since dyspnea
and pulmonary edema in relation to conditions other than
OKT3 treatment have been shown to be induced by comple-
ment activation products [14—18], the aim of the present study
was to delineate the role of complement in the pathogenesis of
clinical side effects of treatment with OKT3.
In this study we provide evidence that the first administration
of OKT3 activates human complement in vivo. Subsequent
doses of OKT3 do not activate complement most likely because
the target for this anti-CD3 monoclonal antibody, namely
circulating T lymphocytes, are then no longer present [29]. We
also show that this activation occurs via the classical pathway
and coincides with temporary sequestration of granulocytes in
the pulmonary vasculature and disappearance of granulocytes
from the circulation. Furthermore, we demonstrate that neutro-
phils are indeed activated immediately after the first dose of
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Fig. 7. In vitro aggregation of granulocytes and lymphocytes by OKT3 and autologous serum. A. Aggregation of granulocytes and lymphocytes
upon addition of OKT3 (1 g/ml) and fresh autologous serum as complement source. B. This aggregation did not occur when heat-inactivated serum
was used instead of fresh serum. C. A high power photomicrograph of an aggregate of lymphocytes and granulocytes.
OKT3, which is probably at least in part induced by comple-
ment activation products [41—43].
In vitro C5a induces degranulation of both azurophilic gran-
ules which contain elastase, and specific granules which contain
lactoferrin [43, 44]. In sepsis patients plasma levels of elastase-
al-antitrypsin as well as lactoferrin are increased, but only the
former appeared to correlate with plasma C3a-desarg levels
[25], suggesting a role for complement in the release of azuro-
philic granules in sepsis. We propose that complement activa-
tion is responsible for the early release of elastase in the OKT3
treated patients for the following reasons: plasma C3a-desarg
levels showed a fourfold increase as compared to pre-treatment
values already at 15 minutes after the first dose of OKT3. At
that moment no release of TNF, IL-6 or IL-8 had yet occurred.
Therefore, complement activation products were in fact the
earliest agonist for degranulation of neutrophils that were
detectable in the circulation. In addition, in the single patient
who did not show any increase in circulating cytokines in
response to the first dose of OKT3, but who did show comple-
ment activation, an early increase in plasma elastase-al-anti-
trypsin levels was indeed observed. However, this increase was
not followed by a sustained elevation of elastase-al-antitrypsin
levels as was observed in the other OKT3 treated patients, and
plasma levels of lactoferrin did not increase at all. This indicates
the necessity of cytokine release for sustained activation of
neutrophils.
Additional mediators that may be responsible for activation
of neutrophils following the first dose of OKT3 include the
cytokines TNFa [45, 461 and IL-8 [47, 48]. An increase in
circulating TNF levels has been described in several reports on
side effects caused by OKT3 [3, 4] and is also found in our
study. We also demonstrate that this increase of plasma TNF
levels is followed by a significant elevation of serum IL-6 and
IL-8 levels with peak levels at two hours after the first dose of
OKT3. This cytokine release probably results from OKT3
activated T cells [6], but may also be due to stimulation of
monocytes by Fc-receptor crosslinking [49, 50]. In addition,
release of IL-6 and IL-8 may have been induced by the elevated
circulating levels of TNF [47, 48].
In vitro, both TNF [45, 46] and IL-8 [47] can induce degran-
ulation of both azurophilic and specific granules of neutrophils.
In other in vivo studies, in which healthy subjects were chal-
lenged with either rh-TNFa [51] or endotoxin [52], elevated
plasma levels of both degranulation products from neutrophils
were shown in the presence of elevated levels of circulating
TNF and IL-6. Some additional evidence that release of cyto-
kines contributes to the sustained activation of neutrophils
during treatment with OKT3 was obtained from the one patient
in whom, in the absence of elevated levels of circulating
cytokines, plasma lactoferrin levels did not change at all,
whereas plasma elastase-csl-antitrypsin levels were only in-
creased during the first two hours after the first dose of OKT3.
This was in sharp contrast with the findings obtained in the
other eight patients treated with OKT3.
In the present study we also demonstrate immediate seques-
tration of granulocytes in the lungs upon the first dose of OKT3.
Pulmonary accumulation of granulocytes may have been
caused by adhesion of C5a activated neutrophils to the vascular
endothelium [41, 42] and/or sequestration of cell-aggregates into
the pulmonary vasculature. Indeed we demonstrated in vitro
immunocytoadherence of granulocytes and lymphocytes upon
addition of OKT3 and complement, which may suggest that
aggregates of these cells are also involved in vivo. Our findings
suggest that complement activation and subsequent pulmonary
sequestration of activated granulocytes may be involved in the
development of acute respiratory side effects that typically
occur only after the first dose of OKT3. Three of nine patients
treated with OKT3 became dyspneic despite preadministration
of MPNS and careful prevention of fluid overload. The extent of
complement activation or pulmonary accumulation of granulo-
cytes in these three patients was not different from the other six
OKT3 treated patients. Some subclinical respiratory distress
may have occurred in these other patients, since a decrease in
measured arterial P02 was reported by Busing et al in 16 out of
18 patients; in the majority of cases (12 out of 16) this occurred
as soon as 15 minutes after the first dose of OKT3 [9]. Although
the present study does not prove that neutrophils migrate into
the pulmonary interstitium, even without interstitial migration
the pulmonary vascular endothelium may have been damaged
by azurophilic degranulation products of the sequestered neu-
trophils. To demonstrate migration of activated neutrophils into
the pulmonary interstitium or the alveolar space, bronchoalve-
olar lavage studies would be required. However, this would be
too heavy a burden for patients receiving OKT3.
Occasionally, patients may develop more severe and even life
threatening respiratory distress during treatment with OKT3
[7—91. Our data do not allow definite conclusions whether this
condition is solely due to complement activation and pulmonary
sequestration of neutrophils, or if the release of cytokines such
as TNFa is also involved [3—5]. Clinical and experimental
studies on the pathogenesis of adult respiratory distress syn-
drome have indicated that this syndrome may result from direct
toxic effects of complement and/or cytokines on pulmonary
endothelial cells [10, 11], or from endothelial damage brought
about by activated neutrophils [14—18]. Since all the above-
mentioned agents are present upon the first dose of OKT3, they
will probably execute their noxious effects in concert with each
other.
In conclusion, we demonstrate complement activation in
patients upon administration of the first dose of OKT3 and
provide in vitro evidence in support of the hypothesis that this
activation has been caused by OKT3-coated T cells. Further-
more, we show immediate degranulation and sequestration of
granulocytes in the pulmonary vasculature upon the first ad-
ministration of OKT3. We suggest that these phenomena may
play a role in the development of (immediate) respiratory side
effects during treatment with OKT3. However, further work is
needed to study the role of complement activation, relative to
1148 Raasveld et al: Complement activation during OKT3 treatment
that of other mediators, in the development of pulmonary
symptoms after OKT3 administration.
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